Form
SCHEDULE 13G
Passive or exempt beneficial ownership filing.
FIDELION DIAGNOSTICS PTE. LTD. - 28 Nov 2025 SCHEDULE 13G Report for BioNexus Gene Lab Corp COMMON STOCK, NO PAR VALUE (BGLC)
- Filing manager
- FIDELION DIAGNOSTICS PTE. LTD.
- Reporting owner
- Fidelion Diagnostics Pte. Ltd.
- Beneficially owned shares
- 392,329 shares
- Large-stake signal
-
Ownership
13%Beneficial ownership of this reported class.
Shares
392,329 sharesShares beneficially owned as disclosed.
Event date
28 Nov 2025Date tied to the ownership event or amendment.
Accepted by SEC
22 Oct 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 13%
- Symbol
- BGLC
- Shares outstanding
- 2,927,828 shares
- SEC form
- SCHEDULE 13G
- Accepted by SEC
- 22 Oct 2026, 18:33:19 UTC
- Event date
- 28 Nov 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
4 source fields
Filing notes and source
Key filing fact
FIDELION DIAGNOSTICS PTE. LTD. disclosed 13% ownership in BioNexus Gene Lab Corp COMMON STOCK, NO PAR VALUE (BGLC) on 28 Nov 2025.
Key facts
- FIDELION DIAGNOSTICS PTE. LTD. filed SCHEDULE 13G for BioNexus Gene Lab Corp COMMON STOCK, NO PAR VALUE (BGLC).
- Disclosed ownership: 13%.
- Date of event: 28 Nov 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 22 Oct 2026, 18:33.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (4)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Fidelion Diagnostics Pte. Ltd. | 13% | 392,329 | 392,329 | 0 | /s/ Ling Xiao | Ling Xiao - Director | |
| MOLECULE BIO LLC | 13% | 392,329 | 0 | 392,329 | /s/ Ling Xiao | Ling Xiao - Director | |
| XIAO LING | 13% | 392,329 | 0 | 392,329 | /s/ Ling Xiao | Ling Xiao, Owner | |
| RAINY MORNING TECHNOLOGY (HONG KONG) LIMITED | 13% | 392,329 | 0 | 392,329 | /s/ Wenlong Tan | Wenlong Tan - Director |
CIK / CUSIP context first